Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen

Maurizio Musso, Giuseppe Messina, Nicola Di Renzo, P. Di Carlo, U. Vitolo, Renato Scalone, Gianpaolo Marcacci, Potito Rosario Scalzulli, Tiziana Moscato, R. Matera, A. Crescimanno, Stella Santarone, E. Orciuolo, Anxur Merenda, V. Pavone, Domenico Pastore, Daniela Donnarumma, Angelo Michele Carella, Chiara Ciochetto, Nicola Cascavilla & 5 others Anna Mele, Francesco Lanza, Massimo Di Nicola, Erminio Bonizzoni, Antonio Pinto

Research output: Contribution to journalArticle

Abstract

High-dose chemotherapy (HDT) with autologous stem cell transplantation is the standard of care for relapsed/refractory (RR) Hodgkin lymphoma (HL). Given that HDT may cure a sizeable proportion of patients refractory to first salvage, development of newer conditioning regimens remains a priority. We present the results of a novel HDT regimen in which carmustine was substituted by a third-generation chloroethylnitrosourea, fotemustine, with improved pharmacokinetics and safety (FEAM; fotemustine, etoposide, cytarabine, melphalan) in 122 patients with RR-HL accrued into a prospective registry-based study. Application of FEAM resulted in a 2-year progression-free survival (PFS) of 73·8% [95% confidence interval (CI), 0·64-0·81] with median PFS, overall survival and time to progression yet to be reached. The 2-year risk of progression adjusted for the competitive risk of death was 19·4% (95% CI, 0·12-0·27) for the entire patient population. Most previously established independent risk factors, except for fluorodeoxyglucose (18FFDG)-uptake, were unable to predict for disease progression and survival after FEAM. Although 32% of patients had 18FFDG-positrin emission tomography-positive lesions before HDT, the 2-year risk of progression adjusted for competitive risk of death was 19·4% (95% CI; 0·12-0·27). No unusual acute toxicities or early/late pulmonary adverse events were registered. FEAM emerges as an ideal HDT regimen for RR-HL patients typically pre-exposed to lung-damaging treatments.

Original languageEnglish
Pages (from-to)111-121
Number of pages11
JournalBritish Journal of Haematology
Volume172
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

fotemustine
Hodgkin Disease
Drug Therapy
Confidence Intervals
Disease-Free Survival
Carmustine
Lung
Melphalan
Survival
Cytarabine
Stem Cell Transplantation
Etoposide
Standard of Care
Registries
Disease Progression
Pharmacokinetics
Tomography
Safety

Keywords

  • Autologous stem cell transplantation
  • Fotemustine
  • High-dose chemotherapy
  • Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. / Musso, Maurizio; Messina, Giuseppe; Di Renzo, Nicola; Di Carlo, P.; Vitolo, U.; Scalone, Renato; Marcacci, Gianpaolo; Scalzulli, Potito Rosario; Moscato, Tiziana; Matera, R.; Crescimanno, A.; Santarone, Stella; Orciuolo, E.; Merenda, Anxur; Pavone, V.; Pastore, Domenico; Donnarumma, Daniela; Carella, Angelo Michele; Ciochetto, Chiara; Cascavilla, Nicola; Mele, Anna; Lanza, Francesco; Di Nicola, Massimo; Bonizzoni, Erminio; Pinto, Antonio.

In: British Journal of Haematology, Vol. 172, No. 1, 01.01.2016, p. 111-121.

Research output: Contribution to journalArticle

Musso, M, Messina, G, Di Renzo, N, Di Carlo, P, Vitolo, U, Scalone, R, Marcacci, G, Scalzulli, PR, Moscato, T, Matera, R, Crescimanno, A, Santarone, S, Orciuolo, E, Merenda, A, Pavone, V, Pastore, D, Donnarumma, D, Carella, AM, Ciochetto, C, Cascavilla, N, Mele, A, Lanza, F, Di Nicola, M, Bonizzoni, E & Pinto, A 2016, 'Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen', British Journal of Haematology, vol. 172, no. 1, pp. 111-121. https://doi.org/10.1111/bjh.13803
Musso, Maurizio ; Messina, Giuseppe ; Di Renzo, Nicola ; Di Carlo, P. ; Vitolo, U. ; Scalone, Renato ; Marcacci, Gianpaolo ; Scalzulli, Potito Rosario ; Moscato, Tiziana ; Matera, R. ; Crescimanno, A. ; Santarone, Stella ; Orciuolo, E. ; Merenda, Anxur ; Pavone, V. ; Pastore, Domenico ; Donnarumma, Daniela ; Carella, Angelo Michele ; Ciochetto, Chiara ; Cascavilla, Nicola ; Mele, Anna ; Lanza, Francesco ; Di Nicola, Massimo ; Bonizzoni, Erminio ; Pinto, Antonio. / Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. In: British Journal of Haematology. 2016 ; Vol. 172, No. 1. pp. 111-121.
@article{3f92e888f81744d683f83cf91dfd699a,
title = "Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen",
abstract = "High-dose chemotherapy (HDT) with autologous stem cell transplantation is the standard of care for relapsed/refractory (RR) Hodgkin lymphoma (HL). Given that HDT may cure a sizeable proportion of patients refractory to first salvage, development of newer conditioning regimens remains a priority. We present the results of a novel HDT regimen in which carmustine was substituted by a third-generation chloroethylnitrosourea, fotemustine, with improved pharmacokinetics and safety (FEAM; fotemustine, etoposide, cytarabine, melphalan) in 122 patients with RR-HL accrued into a prospective registry-based study. Application of FEAM resulted in a 2-year progression-free survival (PFS) of 73·8{\%} [95{\%} confidence interval (CI), 0·64-0·81] with median PFS, overall survival and time to progression yet to be reached. The 2-year risk of progression adjusted for the competitive risk of death was 19·4{\%} (95{\%} CI, 0·12-0·27) for the entire patient population. Most previously established independent risk factors, except for fluorodeoxyglucose (18FFDG)-uptake, were unable to predict for disease progression and survival after FEAM. Although 32{\%} of patients had 18FFDG-positrin emission tomography-positive lesions before HDT, the 2-year risk of progression adjusted for competitive risk of death was 19·4{\%} (95{\%} CI; 0·12-0·27). No unusual acute toxicities or early/late pulmonary adverse events were registered. FEAM emerges as an ideal HDT regimen for RR-HL patients typically pre-exposed to lung-damaging treatments.",
keywords = "Autologous stem cell transplantation, Fotemustine, High-dose chemotherapy, Hodgkin lymphoma",
author = "Maurizio Musso and Giuseppe Messina and {Di Renzo}, Nicola and {Di Carlo}, P. and U. Vitolo and Renato Scalone and Gianpaolo Marcacci and Scalzulli, {Potito Rosario} and Tiziana Moscato and R. Matera and A. Crescimanno and Stella Santarone and E. Orciuolo and Anxur Merenda and V. Pavone and Domenico Pastore and Daniela Donnarumma and Carella, {Angelo Michele} and Chiara Ciochetto and Nicola Cascavilla and Anna Mele and Francesco Lanza and {Di Nicola}, Massimo and Erminio Bonizzoni and Antonio Pinto",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/bjh.13803",
language = "English",
volume = "172",
pages = "111--121",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen

AU - Musso, Maurizio

AU - Messina, Giuseppe

AU - Di Renzo, Nicola

AU - Di Carlo, P.

AU - Vitolo, U.

AU - Scalone, Renato

AU - Marcacci, Gianpaolo

AU - Scalzulli, Potito Rosario

AU - Moscato, Tiziana

AU - Matera, R.

AU - Crescimanno, A.

AU - Santarone, Stella

AU - Orciuolo, E.

AU - Merenda, Anxur

AU - Pavone, V.

AU - Pastore, Domenico

AU - Donnarumma, Daniela

AU - Carella, Angelo Michele

AU - Ciochetto, Chiara

AU - Cascavilla, Nicola

AU - Mele, Anna

AU - Lanza, Francesco

AU - Di Nicola, Massimo

AU - Bonizzoni, Erminio

AU - Pinto, Antonio

PY - 2016/1/1

Y1 - 2016/1/1

N2 - High-dose chemotherapy (HDT) with autologous stem cell transplantation is the standard of care for relapsed/refractory (RR) Hodgkin lymphoma (HL). Given that HDT may cure a sizeable proportion of patients refractory to first salvage, development of newer conditioning regimens remains a priority. We present the results of a novel HDT regimen in which carmustine was substituted by a third-generation chloroethylnitrosourea, fotemustine, with improved pharmacokinetics and safety (FEAM; fotemustine, etoposide, cytarabine, melphalan) in 122 patients with RR-HL accrued into a prospective registry-based study. Application of FEAM resulted in a 2-year progression-free survival (PFS) of 73·8% [95% confidence interval (CI), 0·64-0·81] with median PFS, overall survival and time to progression yet to be reached. The 2-year risk of progression adjusted for the competitive risk of death was 19·4% (95% CI, 0·12-0·27) for the entire patient population. Most previously established independent risk factors, except for fluorodeoxyglucose (18FFDG)-uptake, were unable to predict for disease progression and survival after FEAM. Although 32% of patients had 18FFDG-positrin emission tomography-positive lesions before HDT, the 2-year risk of progression adjusted for competitive risk of death was 19·4% (95% CI; 0·12-0·27). No unusual acute toxicities or early/late pulmonary adverse events were registered. FEAM emerges as an ideal HDT regimen for RR-HL patients typically pre-exposed to lung-damaging treatments.

AB - High-dose chemotherapy (HDT) with autologous stem cell transplantation is the standard of care for relapsed/refractory (RR) Hodgkin lymphoma (HL). Given that HDT may cure a sizeable proportion of patients refractory to first salvage, development of newer conditioning regimens remains a priority. We present the results of a novel HDT regimen in which carmustine was substituted by a third-generation chloroethylnitrosourea, fotemustine, with improved pharmacokinetics and safety (FEAM; fotemustine, etoposide, cytarabine, melphalan) in 122 patients with RR-HL accrued into a prospective registry-based study. Application of FEAM resulted in a 2-year progression-free survival (PFS) of 73·8% [95% confidence interval (CI), 0·64-0·81] with median PFS, overall survival and time to progression yet to be reached. The 2-year risk of progression adjusted for the competitive risk of death was 19·4% (95% CI, 0·12-0·27) for the entire patient population. Most previously established independent risk factors, except for fluorodeoxyglucose (18FFDG)-uptake, were unable to predict for disease progression and survival after FEAM. Although 32% of patients had 18FFDG-positrin emission tomography-positive lesions before HDT, the 2-year risk of progression adjusted for competitive risk of death was 19·4% (95% CI; 0·12-0·27). No unusual acute toxicities or early/late pulmonary adverse events were registered. FEAM emerges as an ideal HDT regimen for RR-HL patients typically pre-exposed to lung-damaging treatments.

KW - Autologous stem cell transplantation

KW - Fotemustine

KW - High-dose chemotherapy

KW - Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84955442571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955442571&partnerID=8YFLogxK

U2 - 10.1111/bjh.13803

DO - 10.1111/bjh.13803

M3 - Article

VL - 172

SP - 111

EP - 121

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -